Table 3.
The response to NY-ESO-1 peptide L9L appears as a result of vaccination with S11L
| Study week | Stimulated with S9C
|
Stimulated with S11L
|
||
|---|---|---|---|---|
| S9C-Tetramer (% CD8+ cells) | ELISPOT T2+S9C (spots/50,000 cells) | L9L-Tetramer (% CD8+ cells) | ELISPOT T2+L9L (spots/50,000 cells) | |
| Prestudy | 0.01% | 6 (2) | 0.02% | 5 (8) |
| Week 2 | 0.00% | 3 (1) | 0.07% | 7 (4) |
| Week 4 | 0.03% | 2 (1) | 0.21% | 42 (35) |
| Week 6 | 0.01% | 9 (11) | 0.44% | 126 (9) |
| Week 8 | 0.03% | 1 (8) | 2.97% | 289 (15) |
CD8+ T cells from patient PI-E01 were presensitized with S9C or S11L and tested at day 10 with tetramers made with S9C or L9L, and by ELISPOT assay with T2 cells pulsed with S9C or L9L (spots for T2 cells without peptide are shown in parentheses). Bold numbers represent detectable increases. No response to S9C was seen in this patient.